
HIMS Stock Forecast & Price Target
HIMS Analyst Ratings
Bulls say
Hims & Hers Health is supported by a multi-engine growth model that pairs branded weight-loss momentum with expanding international scale and new specialty launches, helping offset near-term pressure from lower marketing spend and a sequential subscriber decline. Revenue of $890.4 million in 3Q26 grew 48.6% year over year, while average monthly revenue per subscriber rose to $105 and subscribers reached 2.788 million, signaling strong monetization even as the business reinvests for longer-term leadership. The company’s outlook is reinforced by its direct-to-consumer, self-pay model, deeper partnership access to Zepbound and Wegovy alternatives, and AI-led engagement improvements that management expects will lower cancellations, improve retention, and support operating leverage over time.
Bears say
Hims & Hers Health is facing a negative fundamental setup because revenue growth is increasingly being bought with weaker profitability: 3Q26 revenue of $890.4mm rose 48.6% Y/Y, yet gross margin fell to 57.2% and operating margin slipped to (0.2%) as branded GLP-1 sales and international mix diluted margins. Management also lowered FY26 adjusted EBITDA guidance to $257mm-$277mm and cut 4Q26 revenue and EBITDA below consensus, signaling that heavier marketing, pricing pressure in the UK and Germany, and subscriber deferrals are weighing on near-term earnings power. The company’s direct-to-consumer model remains vulnerable to intense competition, possible regulation around compounding and GLP-1s, and the strain of funding growth while carrying $1,368.0mm of debt against $712.2mm in cash and equivalents.
This aggregate rating is based on analysts' research of Hims & Hers Health and is not a guaranteed prediction by Public.com or investment advice.
HIMS Analyst Forecast & Price Prediction
Start investing in HIMS
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Hims & Hers Health (HIMS) Forecast
HIMS Analyst Forecast & Price Prediction
Start investing in HIMS
Order type
Buy in
Order amount
Est. shares
0 shares